Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Assessment of Neurologic Safety Profile of Immune Checkpoint Inhibitors: Evaluation of Adverse Drug Reaction Reports

Author(s): Atul Khurana, Harikesh Dubey and Mandeep Kumar Arora*

Volume 19, Issue 3, 2024

Published on: 19 January, 2024

Page: [382 - 394] Pages: 13

DOI: 10.2174/0115748863273507231116112824

Price: $65

Abstract

Background: Immune checkpoint inhibitors (ICIs) used in immunotherapy have revolutionized cancer management. However, ICI therapy can come with serious neurologic risks.

Objective: The objective of our study is to analyze the occurrence of neurologic events with ICIs.

Methods: We referred to EudraVigilance (EV) and VigiAccess to evaluate the frequency of individual case safety reports (ICSRs), including neurologic events with ICIs. Data was gathered for a period from the date of ICI’s marketing authorization till 30 January 2023. The computational assessment was conducted with the help of reporting odds ratio (ROR) and its 95% confidence interval (CI).

Results: Overall, 8181 ICSRs in EV and 15905 ICSRs from VigiAccess were retrieved for neurologic events, with at least one ICI as the suspected drug. The majority of the ICSRs were reported for nivolumab, pembrolizumab, and ipilimumab, whereas frequently reported events were neuropathy peripheral, myasthenia gravis, seizure, Guillain-Barre syndrome, paraesthesia, syncope, encephalopathy, somnolence. Under EV, 92% of ICSRs were reported as serious, 10% included fatal outcomes, and nearly 61% cited patient recovery. Atezolizumab (ROR 1.64, 95% CI 1.75- 1.52), cemiplimab (ROR 1.61, 95% CI 1.98-1.3), and nivolumab (ROR 1.38, 95% CI 1.44-1.31) had a considerable increase in the frequency of ICSR reporting. Cerebrovascular accident, posterior reversible encephalopathy syndrome, tremor, and somnolence were identified as potential signals.

Conclusion: ICIs were significantly associated with neurologic risks, which cannot be generalized. A considerable increase in ICSR reporting frequency was observed with atezolizumab, cemiplimab, and nivolumab, while avelumab, pembrolizumab, durvalumab, and cemiplimab were linked with four potential signals. These findings suggest the consideration of a revision of the neurologic safety profile of ICIs. Furthermore, the necessity for additional ad-hoc research is emphasized.

« Previous Next »
Graphical Abstract

[1]
Johnson DB, Manouchehri A, Haugh AM, et al. Neurologic toxicity associated with immune checkpoint inhibitors: A pharmacovigilance study. J Immunother Cancer 2019; 7(1): 134.
[http://dx.doi.org/10.1186/s40425-019-0617-x] [PMID: 31118078]
[2]
Cheng K, Wang Y, Zhou Y, Xia R, Tang L, Liu J. Neurological adverse events induced by immune checkpoint inhibitors in non-small cell lung cancer: Current perspectives and new development. Clin Med Insights Oncol 2021; 15.
[http://dx.doi.org/10.1177/11795549211056261] [PMID: 34866959]
[3]
Zhao Z, Zhang C, Zhou L, Dong P, Shi L. Immune checkpoint inhibitors and neurotoxicity. Curr Neuropharmacol 2021; 19(8): 1246-63.
[http://dx.doi.org/10.2174/1570159X19666201230151224] [PMID: 33380303]
[4]
Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf 2020; 19(4): 479-88.
[http://dx.doi.org/10.1080/14740338.2020.1738382] [PMID: 32126176]
[5]
Marini A, Bernardini A, Gigli GL, et al. Neurologic adverse events of immune checkpoint inhibitors. Neurology 2021; 96(16): 754-66.
[http://dx.doi.org/10.1212/WNL.0000000000011795] [PMID: 33653902]
[6]
Živković SA, Al-Lahham T. Neurologic complications of immune checkpoint inhibitors. Neurology 2022; 18(1): 58-63.
[http://dx.doi.org/10.17925/USN.2022.18.1.58] [PMID: 35168549]
[7]
Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of fda-approved immune checkpoint inhibitors per nccn guidelines with the level of evidence. Cancers 2020; 12(3): 738.
[http://dx.doi.org/10.3390/cancers12030738] [PMID: 32245016]
[8]
Khurana A, Arora MK, Dubey H. Cardiac safety profile of type II kinase inhibitors: Analysis of post-marketing reports from databases of European Medicine Agency & World Health Organization. Daru 2023.
[http://dx.doi.org/10.1007/s40199-023-00464-0] [PMID: 37221442]
[9]
Candore G, Juhlin K, Manlik K, et al. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf 2015; 38(6): 577-87.
[http://dx.doi.org/10.1007/s40264-015-0289-5] [PMID: 25899605]
[10]
Gerbasi ME, Nambiar S, Reed S, et al. Essential tremor patients experience significant burden beyond tremor: A systematic literature review. Front Neurol 2022; 13: 891446.
[http://dx.doi.org/10.3389/fneur.2022.891446] [PMID: 35937052]
[11]
Schneider SA, Tschaidse L, Reisch N. Thyroid disorders and movement disorders—a systematic review. Mov Disord Clin Pract 2023; 10(3): 360-8.
[http://dx.doi.org/10.1002/mdc3.13656] [PMID: 36949803]
[12]
Dirkx MF, Bologna M. The pathophysiology of Parkinson’s disease tremor. J Neurol Sci 2022; 435: 120196.
[http://dx.doi.org/10.1016/j.jns.2022.120196] [PMID: 35240491]
[13]
Louis ED. Essential tremor and the cerebellum. Handb Clin Neurol 2018; 155: 245-58.
[http://dx.doi.org/10.1016/B978-0-444-64189-2.00016-0] [PMID: 29891062]
[14]
Kheetan M, Ogu I, Shapiro JI, Khitan ZJ. Acute and chronic hyponatremia. Front Med 2021; 8: 693738.
[http://dx.doi.org/10.3389/fmed.2021.693738] [PMID: 34414205]
[15]
Alberti S, Chiesa A, Andrisano C, Serretti A. Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: A meta-analysis. J Clin Psychopharmacol 2015; 35(3): 296-303.
[http://dx.doi.org/10.1097/JCP.0000000000000329] [PMID: 25874915]
[16]
Schipper SBJ, Van Veen MM, Elders PJM, et al. Sleep disorders in people with type 2 diabetes and associated health outcomes: A review of the literature. Diabetologia 2021; 64(11): 2367-77.
[http://dx.doi.org/10.1007/s00125-021-05541-0] [PMID: 34401953]
[17]
Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 2019; 38(1): 255.
[http://dx.doi.org/10.1186/s13046-019-1259-z] [PMID: 31196207]
[18]
Albarrán V, Chamorro J, Rosero DI, et al. Neurologic toxicity of immune checkpoint inhibitors: A review of literature. Front Pharmacol 2022; 13: 774170.
[http://dx.doi.org/10.3389/fphar.2022.774170] [PMID: 35237154]
[19]
Gerdes LA, Held K, Beltrán E, et al. CTLA4 as immunological checkpoint in the development of multiple sclerosis. Ann Neurol 2016; 80(2): 294-300.
[http://dx.doi.org/10.1002/ana.24715] [PMID: 27351142]
[20]
Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021; 39(36): 4073-126.
[http://dx.doi.org/10.1200/JCO.21.01440] [PMID: 34724392]
[21]
Mikami T, Liaw B, Asada M, et al. Neuroimmunological adverse events associated with immune checkpoint inhibitor: A retrospective, pharmacovigilance study using FAERS database. J Neurooncol 2021; 152(1): 135-44.
[http://dx.doi.org/10.1007/s11060-020-03687-2] [PMID: 33423151]
[22]
Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature. Ann Oncol 2017; 28(2): 377-85.
[http://dx.doi.org/10.1093/annonc/mdw558] [PMID: 28426103]
[23]
Dalakas MC. Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord 2018; 11: 175628418799864.
[http://dx.doi.org/10.1177/1756286418799864] [PMID: 30245744]
[24]
Ruggiero R, Fraenza F, Scavone C, et al. Immune checkpoint inhibitors and immune-related adverse drug reactions: Data from italian pharmacovigilance database. Front Pharmacol 2020; 11: 830.
[http://dx.doi.org/10.3389/fphar.2020.00830] [PMID: 32581796]
[25]
Noseda R, Bonaldo G, Motola D, Stathis A, Ceschi A. Adverse event reporting with immune checkpoint inhibitors in older patients: Age subgroup disproportionality analysis in vigibase. Cancers 2021; 13(5): 1131.
[http://dx.doi.org/10.3390/cancers13051131] [PMID: 33800813]
[26]
Raschi E, Mazzarella A, Antonazzo IC, et al. Toxicities with immune checkpoint inhibitors: Emerging priorities from disproportionality analysis of the FDA adverse event reporting system. Target Oncol 2019; 14(2): 205-21.
[http://dx.doi.org/10.1007/s11523-019-00632-w] [PMID: 30927173]
[27]
Farina A, Villagrán-García M, Honnorat J. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management. Rev Neurol 2023; 179(5): 506-15.
[http://dx.doi.org/10.1016/j.neurol.2023.03.003]
[28]
Staff NP, Cavaletti G, Islam B, Lustberg M, Psimaras D, Tamburin S. Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst 2019; 24(S2): S26-39.
[http://dx.doi.org/10.1111/jns.12335]
[29]
Gornstein EL, Schwarz TL. Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects. Exp Neurol 2017; 288: 153-66.
[http://dx.doi.org/10.1016/j.expneurol.2016.11.015] [PMID: 27894788]
[30]
Pérez-Moreno MA, Galván-Banqueri M, Flores-Moreno S, Villalba-Moreno Á, Cotrina-Luque J, Bautista-Paloma FJ. Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer. Int J Clin Pharm 2014; 36(3): 476-87.
[http://dx.doi.org/10.1007/s11096-014-9920-2] [PMID: 24590919]
[31]
Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2022, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw 2022; 20(4): 387-405.
[http://dx.doi.org/10.6004/jnccn.2022.0020] [PMID: 35390769]
[32]
Maus MV, Alexander S, Bishop MR, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 2020; 8(2): e001511.
[http://dx.doi.org/10.1136/jitc-2020-001511] [PMID: 33335028]
[33]
Zhou C, Peng S, Lin A, et al. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine 2023; 59: 101967.
[http://dx.doi.org/10.1016/j.eclinm.2023.101967] [PMID: 37131541]
[34]
Sisi M, Fusaroli M, De Giglio A, et al. Psychiatric adverse reactions to anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer: analysis of spontaneous reports submitted to the FDA adverse event reporting system. Target Oncol 2022; 17(1): 43-51.
[http://dx.doi.org/10.1007/s11523-021-00865-8] [PMID: 35025076]
[35]
Farooq MZ, Aqeel SB, Lingamaneni P, et al. Association of immune checkpoint inhibitors with neurologic adverse events. JAMA Netw Open 2022; 5(4): e227722.
[http://dx.doi.org/10.1001/jamanetworkopen.2022.7722] [PMID: 35438755]
[36]
Chintalacheruvu LM, Naha K, Chilluru VK, Doll DC. Review of neurological side effects associated with checkpoint inhibitor therapy in cancer patients. J Clin Oncol 2020; 38(S5): 72-2.
[http://dx.doi.org/10.1200/JCO.2020.38.5_suppl.72]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy